Enterovirus 71 (EV71) infection can induce encephalitis. Overt immune responses is suspected to cause severe symptoms, so anti-inflammatory agents, corticosteroids have been recommended for treatment. However, one clinical study reported that treatment with glucocorticoids, dexamethasone (Dex) exacerbates disease severity. Here we investigated Dex treatment on EV71 infection using the murine model and found that both long-term (14-day) and short-term (4-day) Dex treatment starting from 1 or 3 days postinfection increased the mortality and disease severity of infected mice. Dex treatment starting from 4 or 8 days postinfection did not affect mouse mortality and disease severity. Early Dex treatment starting from 1 day postinfection caused atrophy and enhanced apoptosis in lymphoid organs to decrease the numbers of lymphocytes (CD4 þ T cells, CD8 þ T cells, and CD19 þ B cells) and to increase viral loads in infected tissues of mice. Our results demonstrate that Dex treatment has no beneficial effect on EV71 infection.
Introduction
Enterovirus 71 (EV71) is a member of the family Picornaviridae. EV71 infects humans by the fecal-oral route and can induce fever and mild symptoms, such as herpangina or hand-foot-and-mouth disease (Chang et al., 2007; Ho et al., 1999; Huang et al., 1999) . It can also infect the central nervous system (CNS) to induce neurological manifestations, including aseptic meningitis, encephalomyelitis, brainstem encephalitis, and acute flaccid paralysis, especially in young children. Brainstem encephalitis combined with pulmonary edema complications often cause death or longterm neurological sequelae (Chang et al., 2007) . Widespread and deadly EV71 outbreaks have been reported, particularly in the Asia-Pacific region, which are estimated to have infected millions of children and have caused death and severe neurological sequelae in thousands of children since the last decade (Qiu, 2008; Solomon et al., 2010) . As vaccines and antiviral therapies specific for EV71 are not available, EV71 infection is becoming endemic in areas with outbreaks and has massive potential for explosive epidemics.
Currently, there is no effective treatment for EV71-infected patients with fatal symptoms, because the pathogenesis remains elusive. Immature or insufficient immunity has been suspected to associate with increased morbidity and mortality in infected patients, as infants and young children are highly susceptible to fatal infection. The finding of lymphopenia with decreased levels of CD4 þ and CD8 þ T cells in infected patients with brainstem encephalitis and pulmonary edema supports this notion (Chang et al., 2006; Wang et al., 2003a) . However, some clinical studies suggested that elevated cellular immunity with a predominance of lymphocytes may be linked with unfavorable outcomes (Chang et al., 2004; Hsia et al., 2005; Lum et al., 1998; Wang et al., 1999; Yan et al., 2000) . In addition, elevated cytokine and chemokine levels are detected in encephalitis patients (Lin et al., , 2003 Wang et al., 2003a Wang et al., , 2006 Wang et al., , 2008 . Cytokine storm has therefore been proposed to contribute to severe complications in infected patients (Lin et al., , 2003 , so anti-inflammatory therapy is recommended for treatment . Moreover, one report indicates that immunopathology may induce neurological diseases and showed that late corticosteroid treatment about three weeks after infection improved the neurological illness (opso-myoclonus syndrome) of one patient (McMinn et al., 2001) . Later, another report of patients with pulmonary edema and respiratory failure demonstrated that corticosteroid treatment improves the long-term neurological deficits of three patients (Nolan et al., 2003) . Nevertheless, one recent report with 134 cases finds that early use of glucocorticoids, such as dexamethasone (Dex), by rural practitioners to treat fever in outpatients is associated with increased risk of severe disease or death in China during 2008 outbreak (Ma et al., 2010) . Steroid treatment is also suspected to link with a significant number of fatal cases in Cambodia during 2012 outbreak (Seiff, 2012) . Clinical reports regarding the effect of corticosteroid treatment on EV71 disease progression remains unclear. The present study was therefore designed to examine the effect of Dex treatment in vivo because of the paucity of reports on this issue. Using a murine infection model, our results showed that early Dex treatment increases EV71 lethality in mice, which may explain the increased mortality of infected patients in China during 2008 outbreak and in Cambodia during 2012 outbreak (Ma et al., 2010; Seiff, 2012) .
Results

Early Dex treatment increases the mortality and tissue viral loads of EV71-infected mice
It has been reported that the rural practitioners in village clinics of China prescribed Dex to treat fever in child outpatients during EV71 outbreak (Ma et al., 2010) . We therefore tested Dex treatment on infected mice that developed fever. Virus infection induces viremia or interferon, which can induce fever. As it is difficult to measure temperature in mice, we used the presence of viremia or interferon as the indication of fever in infected mice. In the present study, 14-day-old C57BL/6J mice were infected with 8 Â 10 4 PFU/mouse of EV71. Infectious virus was detected in the mouse blood with 4 Â 10 3 , 1 Â 10 3 , and 2 Â 10 2 PFU/ml at days 1, 4, and 6 postinfection (p.i.), respectively. Additionally, our previous report detected interferon-α in sera of infected mice from 10 min to 3 days p.i. (Liu et al., 2005) . Thus, we started Dex treatment from day 1 p.i. A previous study showed that the effects of Dex on herpes simplex virus-infected mice were depended on the timing of the treatment (Sergerie et al., 2007) . Dex treatment starting from day 1 p.i. increased the mortality of infected mice, while Dex treatment starting from day 3 p.i. reduced the mortality of infected mice. This prompted us to treat mice with Dex (6.5 mg/kg/day in one shot) at different time points after infection (from days 1, 3, 4, or 8 to 14 p.i.) or with phosphate-buffered saline (PBS) from days 1 to 14 p.i. (Fig. 1A ). There were eight to nice mice in each group. The survival rates of infected mice treated with Dex starting from days 4 or 8 p.i. or with PBS were comparable and about 90% ( Fig. 1B) . Infected mice treated with Dex starting from day 3 p.i. and, especially from day 1 p.i. displayed signs of encephalitis as manifested by hunched posture, lethargy, hind limb paralysis, and ataxia around days 5 to 6 p.i. (Fig. 1C ) with final survival rates of 50% and 12%, respectively, by day 30 p.i. (Fig. 1B) . Dex treatment starting from day 1 p.i. significantly increased the mortality and disease severity of infected mice when compared with PBS treatment (p o0.05). In separate experiments, tissues of infected mice treated with PBS or Dex from day 1 p.i. (n ¼3 to 6 samples per time point in each group) were harvested to determine viral titers ( Fig. 1D ). Viral titers in peripheral organs (heart, lung, liver, intestine, kidney, spleen, and thymus), CNS tissues (brain without the brainstem region, brain stem, and spinal cord), and blood of Dex-treated mice were higher than those of PBS-treated mice almost at all the time points (2, 4, 6, or 8 days p.i.) examined.
Short-term Dex treatment increases the mortality and tissue viral loads of EV71-infected mice
Short-term (three-to four-day) Dex treatment was prescribed by the rural practitioners in village clinics of China to treat fever in child outpatients (Ma et al., 2010) . We therefore tested the effect of short-term Dex treatment by giving infected mice PBS (n¼ 9) or Dex (n ¼8) for 3 days from days 1 to 4 p.i. ( Fig. 2A ). All infected mice treated with Dex succumbed to death within 14 days p.i. (Fig. 2B ) with a final survival rate significantly lower than that of infected mice treated with PBS by 78% (p o0.001). The disease scores of infected mice treated with Dex were also significantly higher than those of infected mice treated with PBS ( Fig. 2C ; po 0.05). Viral titers in peripheral organs (heart, lung, liver, intestine, kidney, and spleen) and CNS tissues (brain without the brainstem region, brain stem, and spinal cord) of Dex-treated mice were all higher than those of PBS-treated mice at days 6 and 8 p.i. 
Early Dex treatment increases the mortality of severely infected mice
Dex treatment has been recommended for patients suffering from severe symptoms, brainstem encephalitis and pulmonary edema with a survival rate of less than 30% Ho et al., 1999) . To determine the effect of Dex treatment on severely infected mice with a low survival rate, we infected mice with a high viral dose of 6 Â 10 5 PFU/mouse. Infected mice were treated with Dex from days 1 or 4 to 14 p.i. or with PBS from days 1 to 14 p.i. (Fig. 3A ). There were eight, ten, and nine mice in each group, respectively. The survival rates of infected mice treated with Dex from day 4 p.i. or with PBS were comparable and about 30% ( Fig. 3B ). All infected mice treated with Dex from day 1 p.i. succumbed to death within 10 days p.i., with a survival rate significantly lower than that of infected mice treated with PBS (po0.001).
Dex treatment causes atrophy in lymphoid organs and reduces lymphocyte numbers in infected organs
Previous studies showed that Dex reduced T and B cells (Ashwell et al., 2000; Merino et al., 1994) . In the present study, we observed that the sizes of thymus and spleen were reduced in Dex-treated mice. Therefore, we examined the effect of Dex treatment starting from day 1 p.i. on the lymphoid organs of mock-infected and infected mice. The thymus weights of PBStreated mice infected with or without EV71 were constant and comparable from days 2 to 6 p.i. (at the age of 16-20 days old) ( Fig. 4A ). Dex treatment significantly decreased the thymus weights of mock-infected and infected mice to a similar degree from days 2 to 6 p.i. when compared with PBS treatment (p o0.05). The spleen weights of mock-infected mice treated with PBS continued to increase from days 2 to 6 p.i. (Fig. 4B ). EV71 infection did not affect the spleen weights from days 2 to 4 p.i., but slightly decreased the weights at day 6 p.i. (p4 0.05). Dex treatment significantly decreased the spleen weights of mock-infected and infected mice to a similar degree at days 4 and 6 p.i. when compared with PBS treatment (p o0.001).
Our previous report found that all three types of lymphocytes, CD4 þ T cells, CD8 þ T cells, and B cells are important in protecting mice from EV71 infection, as mice deficient in any of these cells displayed high mortality rates and tissue viral loads (Lin et al., 2009; Wang et al., 2012) . Because the spleen has all three types of lymphocytes, we next determined the lymphocyte types and levels in the mouse spleen affected by Dex treatment. Spleens of mock-infected and infected mice treated with PBS or Dex from day 1 p.i. were harvested at day 7 p.i., when elevated tissue viral loads were detected in Dex-treated mice. Flow cytometric analyses showed that Dex treatment alone or EV71 infection alone significantly decreased the mean numbers of CD4 þ T cells, CD8 þ T cells, and CD19 þ B cells in mouse spleens ( Fig. 4C ; p o0.001). Dex treatment further reduced levels of CD4 þ T cells, CD8 þ T cells, and CD19 þ B cells in spleens of infected mice when compared with PBS treatment. We also quantified lymphocytes in the brain. Results showed that EV71 infection increased the mean numbers of CD4 þ T cells, CD8 þ T cells, and CD19 þ B cells in brains at day 7 p.i. (Fig. 4D ). Dex treatment reduced the influx of all three types of lymphocytes in brains of infected mice. Additional results showed that short-term Dex treatment (from days 1 to 4 p.i.) was as efficient as the long-term Dex treatment in decreasing the mean numbers of CD4 þ T cells, CD8 þ T cells, and CD19 þ B cells in spleens of infected mice when compared with PBS treatment at day 7 p.i. (Fig. 5 , p o0.05).
Dex treatment and EV71 infection collaborates to enhance apoptosis and to decrease the expression of anti-apoptotic factor Bcl-xL in lymphoid organs
Previous studies showed that Dex induced apoptosis in T and B cells (Andreau et al., 1998; Ashwell et al., 2000) . We assessed apoptosis in the spleens and thymuses of mock-infected and infected mice treated with PBS or Dex from day 1 p.i. by detecting the expression of cleaved caspase-3, an apoptosis marker, using western blotting. In the mouse spleen, Dex treatment alone or EV71 infection alone slightly increased cleaved caspase-3 levels at day 4 p.i. (Fig. 6A ; p4 0.05). Dex treatment significantly increased the cleaved caspase-3 level in infected mice when compared with Dex treatment alone or EV71 infection alone (p o0.05). Similar results were observed in the mouse thymus at day 2 p.i. (Fig. 6B ). Results of cleaved caspase-3 obtained from the thymus and spleen showed that Dex treatment and EV71 infection collaborates to enhance apoptosis in lymphoid organs. We also measured the expression of cleaved caspase-3 levels in spleen lymphocytes. Flow cytometric analyses detected enhanced levels of cleaved caspase-3 in CD4 þ T cells, CD8 þ T cells, and CD19 þ B cells in the spleen of infected mice treated with Dex when compared with mockinfected mice treated with PBS at day 4 p.i. (Fig. 6C ; p o0.01), showing that enhanced apoptosis was observed in all three types of lymphocytes.
As Dex has been shown to induce apoptosis by decreasing the expression of anti-apoptotic factor, Bcl-xL in human B (acute lymphoblastic leukemia) cell lines (Laane et al., 2007) , we therefore assayed the Bcl-xL level in the spleen. Dex treatment alone or EV71 infection alone decreased spleen Bcl-xL levels with a significant difference found in EV71 infection when compared with mock-infected mice treated with PBS ( Fig. 6D; p o0.05 ). Dex treatment further and significantly increased the spleen Bcl-xL level in infected mice when compared with Dex treatment alone or EV71 infection alone (p o0.05).
The effects of Dex treatment on cytokine and chemokine expression in the serum and brain of infected mice vary 2003; Wang et al., 2003a Wang et al., , 2006 Wang et al., , 2008 has promoted the recommendation of using anti-inflammatory therapy for treatment . We therefore examined the effects of Dex treatment starting from day 1 p.i. on cytokine and chemokine expression in infected mice. Dex treatment increased the serum interleukin (IL)-6 level at day 4 p.i. and brain IL-6 levels at days 4 and 6 p.i. in infected mice with significant differences found at day 4 p.i. for both serum and brain IL-6 levels when compared with PBS treatment (Fig. 7A B; p o0 .05). Dex treatment reduced serum levels of antiviral cytokine, interferon (IFN)-β in infected mice at days 2 and 4 p.i. (Fig. 7C) , although the differences did not reach statistical significance when compared with PBS treatment. The brain IFN-β levels of infected mice treated with Dex or PBS were comparable at days 2 and 4 p.i. (Fig. 7D) . The serum and brain IFN-γ levels in infected mice treated with Dex or PBS were not significantly different at days 4 and 6 p.i. (data not shown). Dex treatment significantly increased the serum CXC chemokine ligand 10 (CXCL10; IFN-γ-inducible protein 10 [IP-10]) level at day 4 p.i. and brain CXCL10 levels at days 4 and 6 p.i. in infected mice when compared with PBS treatment (Fig. 7E F; p o0 .05). Dex treatment significantly increased the serum level of chemokine (C-C motif) ligand 5 (CCL5), also known as RANTES (regulated on activation, normal T cell expressed and secreted), at day 4 p.i., but significantly reduced the serum CCL5 level at day 2 p.i. and the brain CCL5 level at day 6 p.i. in infected mice when compared with PBS treatment (Fig. 7G H; p o0.05 ).
Discussion
Previous clinical reports regarding the effect of corticosteroid treatment on EV71 disease progression are unclear. The present study using the murine model shows that early Dex treatment starting from days 1 or 3 p.i. increased the mortality, disease severity, and tissue viral loads of infected mice. Additionally, late Dex treatment starting from days 4 or 8 p.i. failed to improve the disease severity of infected mice. Our results provide evidence that Dex treatment has no beneficial effect on EV71 infection in mice.
Dex is a potent anti-inflammatory steroid used in the clinic. In EV71-infected patients, up to 50 mg/kg/day of Dex has been used to treat fever (Ma et al., 2010) . Dex usage at the dose of 10 mg/kg/day has been shown to affect the survival of herpes simplex virus-infected mice (Sergerie et al., 2007) . We have tested two doses (6.5 and 1.5 mg/ kg/day), and both doses failed to affect the body weight and survival of mock-infected mice. Early treatment with Dex at the dose of 6.5 mg/ kg/day, but not of 1.5 mg/kg/day, increased the mortality of infected mice, so the dose of 6.5 mg/kg/day was used for further investigation. Our mouse results are consistent with the recent clinical finding, which showed that early use of glucocorticoids, Dex to treat fever in outpatients is associated with increased risk of severe disease or death (Ma et al., 2010) . During the first three days of EV71 infection in mice, viral tiers in CNS tissues were increased (Fig. 1D) , the spleen weight continued to increase (Fig. 4B) , and the serum level of antiviral cytokine (IFN-β) was elevated (Fig. 7C) , when compared with measurements from days 4 or 8 p.i. These results could explain why Dex treatment starting from days 1 or 3 p.i., but not from days 4 or 8 p.i., increased the mortality rates of infected mice.
Our previous report showed that all three types of lymphocytes (CD4 þ T cells, CD8 þ T cells, and B cells) function in decreasing the mortality and tissue viral loads of infected mice (Lin et al., 2009 ). In addition, we observed spleen atrophy and reduced lymphocyte numbers in the spleen of infected mice (Shen et al., 2013; Wang et al., 2004) , while elevated lymphocyte numbers were detected in the non-lymphoid organ, such as the brain, of infected mice (Lin et al., 2009; Shen et al., 2013) . In the past, we assumed that the reduced lymphocyte numbers in the spleen were due to the migration of lymphocytes to non-lymphoid organs of infected mice. However, in this study, we were surprised to find that EV71 infection induced apoptosis in lymphoid organs effectively when compared with Dex treatment, a known apoptosis inducer of lymphocytes ( Fig. 6A and B) . Moreover, Dex further enhanced apoptosis in lymphoid organs and reduced CD4 þ T cells, CD8 þ T cells, and B cells in infected organs of mice, showing why Dex treatment increased the mortality and tissue viral loads of EV71-infected mice.
EV71 has been shown to infect lymphocytes in human peripheral blood mononuclear cells as determined by the expression of viral antigen on the cell surface (Chen and Yeh, 2009 ). EV71 has also been shown to replicate in human T cell lines, such as Jurkat T cells (Nishimura et al., 2009) . In mice, we assessed whether EV71 can infect T cells in vivo by detecting the expression of viral antigen on the surface of CD4 and CD 8 T cells in the spleen of infected mice using flow cytometry, but we failed to detect it. Our unpublished results found that EV71 infection can activate lymphocytes in vivo by enhancing the expression of CD69 (activation marker) on the surface of CD4 and CD 8 T cells and the expression of CD138 (activation marker) on the surface of CD19-postivie B cells in the spleen of infected mice. Lymphocyte activation can lead to cell death due to apoptosis (Green et al., 2003) . Accordingly, it is very likely that EV71 infection causes apoptosis of lymphoid cells by promoting activation-induced cell death.
Dex has been shown to induce apoptosis by decreasing the expression of anti-apoptotic factor, Bcl-xL in human B cell lines (Laane et al., 2007) and by enhancing the expression of proapoptotic factor, Bim in T-cell lymphoma lines (Wang et al., 2003b) . EV71 infection has been shown to induce apoptosis by increasing the expression of pro-apoptotic factor, Bax in the human (RD) cell line (Sun et al., 2011) . Surprisingly, we found comparable levels of Bim and Bax in the spleens of mock-infected mice and infected mice treated with or without Dex by western blotting (data not shown). Of note, both Dex and EV71 infection reduced Bcl-xL expression. Moreover, Dex and EV71 infection collaborated to further decrease Bcl-xL expression. These results suggest that Dex alone, EV71 infection alone, and Dex plus EV71 infection may induce apoptosis by reducing Bcl-xL expression in mouse lymphoid organs in a mechanism, which is different from those reported previously by in vitro studies (Laane et al., 2007; Sun et al., 2011; Wang et al., 2003b) .
Anti-inflammatory therapy has been recommended to treat EV71-infected patients with severe symptoms, as high levels of cytokines, such as IL-6 and IFN-γ, are detected in brainstem Fig. 4 . The effects of Dex treatment or/and EV71 infection on lymphoid organ weights and lymphocyte levels in infected organs. Mice were infected with 8 Â 10 4 PFU/mouse of EV71 (EV71) or mock-infected (Mock) and given one shot per day of PBS or Dex from day 1 postinfection (p.i.). The weights of thymus (A) and spleen (B) at the indicated times are shown. The numbers of CD4 þ T cells, CD8 þ T cells, and CD19 þ B cells in the spleen (C) and brain (D) at day 7 p.i. were determined by flow cytometry. Data show means 7 SE (error bars) of three to nine samples per data point or group. n p o 0.05, nn p o 0.01, and nnn p o0.001, via a Student t test compared with samples harvested from mock-infected mice treated with PBS at the same time point (A and B) or between the indicted groups (C and D). encephalitis patients (Lin et al., , 2003 Wang et al., 2003a Wang et al., , 2006 Wang et al., , 2008 . In mice, pro-inflammatory cytokine IL-6 is shown to contribute to EV71 pathogenesis, as depletion of IL-6 using the specific antibody increases the survival of infected mice (Khong et al., 2011) . Dex has been shown to decrease both IFN-β and IFN-γ mRNA levels in the brain of herpes simplex virus-infected mice (Sergerie et al., 2007) . Here we showed that, for cytokines, Dex increased both serum and brain IL-6 levels, reduced the serum level of antiviral cytokine (IFN-β), and failed to affect both serum and brain IFN-γ levels. For chemokines, Dex increased both serum and brain CXCL-10 levels and the serum CCL5 level, but decreased the brain CCL5 level. The effects of Dex on cytokine and chemokine expression varied, depending upon the particular cytokine or chemokine and infection time points examined. For cytokines, Dex increased IL-6 levels and reduced the IFN-β level, which may justify the high mortality rate and tissue viral loads observed in EV71-infected mice treated with Dex. Regarding how EV71 causes death in the infected host, cytokines are shown to be involved, as IL-6 increases the mortality of infected mice (Khong et al., 2011) . In addition, it has been proposed that the neuronal infection by virus, especially in the brain stem may be sufficient Lum et al., 1998) . Destruction of the medullary cardiorespiratory center is believed to be largely responsible. Here we show again that both the cytokine and the neuronal infection by virus are two important causes of death, as Dex treatment increases the lethality of infected mice with elevated viral titers in the brain stem and IL-6 levels.
Previous and present studies found that infected mice and patients are analogous in the aspects, which were examined in this report. They display similar disease progression with signs of CNS infection (encephalitis) as manifested by ataxia and limb paralysis before death (Fig. 1C) (McMinn et al., 2001) . Abundant virus (Fig. 1D ), viral antigens, CD4 þ T cells, CD8 þ T cells, and B cells (Fig. 4) are detected in the brains (Lin et al., 2009) . Elevated cytokine and chemokine levels are found in the sera and brains (Khong et al., 2011; Lin et al., 2002 Lin et al., , 2003 Shen et al., 2013; Fig. 6 . The effects of Dex treatment or/and EV71 infection on cleaved caspase-3 and Bcl-xL expression in mouse lymphoid organs. Mice were infected with 8 Â 10 4 PFU/ mouse of EV71 ( þ) or mock-infected ( À ) and given one shot per day of PBS ( À ) or Dex ( þ ) from day 1 postinfection. Mouse spleens were harvested at day 4 postinfection and mouse thymuses were harvested at day 2 postinfection to determine cleaved caspase-3 (A and B), Bcl-xL (D), and actin levels by western blotting. Top panels show representative blots and bottom panels show quantitated results. The protein levels of mock-infected mice treated with PBS were set as 1. (C) The mean fluorescence intensities (MFI) of cleaved caspase-3 in spleen CD4 þ T cells, CD8 þ T cells, and CD19 þ B cells were determined by flow cytometry. Data show means 7 SE (error bars) of three to nine samples per group. n p o 0.05, nn p o 0.01, and nnn p o0.001, via a Student t test. Wang et al., 2008) . The present mouse study found the following. Early Dex treatment increased the mortality, disease severity, and tissue viral loads of infected mice, which is consistent with the increased risk of severe disease or death of infected patients treated with steroids in China during 2008 outbreak and in Cambodia during 2012 outbreak (Ma et al., 2010; Seiff, 2012) . Dex further enhanced apoptosis in infected lymphoid organs and reduced lymphocyte numbers in infected organs. Our results raise caution over the malpractice of using corticosteroids for infected patients and also help the clinician to assess the risk of such practice. Currently, there is no effective treatment for EV71infected patients with fatal symptoms. Intravenous immunoglobulin (IVIG) has been used for treatment in countries like Taiwan (Wang et al., 2006) . Our previous studies and unpublished results demonstrated that virus-specific antibody, but not IVIG, given before or after infection efficiently reduces the mortality, disease severity, and tissue viral loads of infected mice (Lin et al., 2009; Wang et al., 2012) . Therefore, instead of Dex and IVIG, vaccines and EV71-specific antibody should be better strategies for controlling deadly outbreaks and disease progression in patients.
Materials and methods
The cell, virus, and mice
Human rhabdomyosarcoma (RD) cell line was maintained and propagated according to the instructions of the American Type Culture Collection. EV71 strain M2 was propagated and titrated on RD cell monolayers and used to infect mice as previously described (Li et al., 2008) . All mouse experiment protocols were approved by the Laboratory Animal Committee of National Cheng Kung University. C57BL/6J mice were purchased from the National Laboratory Animal Center in Taiwan, bred, and maintained under specific-pathogen-free conditions in the Animal Center of our college.
Infection and Dex treatment of mice
Fourteen-day-old male and female mice were infected with 8 Â 10 4 or 6 Â 10 5 PFU/mouse of EV71 strain M2 or mock-infected with lysates of uninfected RD cells by intraperitoneal inoculation. Subsequently, mice were given one shot of PBS or Dex (6.5 mg/kg) per day by intraperitoneal injection. The survival of infected mice was monitored. The disease score was graded as follows: 0, healthy; 1, ruffled hair; 2, weakness in hind limbs; 3, paralysis in a single hind limb; 4, paralysis in both hind limbs; and 5, death.
In separate experiments, mice were anesthetized before mouse blood was collected. Then the mice were perfused by intracardial injection of ice-cold PBS, and mouse tissues were harvested. Mouse blood was frozen and sonicated. Mouse tissues were frozen, homogenized, frozen, and sonicated. The resulting samples were assayed for viral titers by plaque assay using RD cell monolayers.
Flow cytometry
Spleens and brains were harvested from mice perfused with PBS. Mouse spleens were homogenized, treated twice with buffer to lyse red blood cells, and washed with RPMI medium containing 10% fetal bovine serum. Mouse brains were harvested and homogenized in PBS containing 0.01 M EDTA and 0.2% bovine serum albumin. The brain homogenates were passed through strainer filters (BD Biosciences). Brain leukocytes were purified by Percoll (GE Healthcare) gradient centrifugation. Freshly isolated leukocytes from mouse spleens and brains were stained with fluorescein isothiocyanate-or phycoerythrin-conjugated control antibodies or antibodies against mouse lymphocyte antigens, CD4 (clone GK 1.5; eBioscience), CD8a (clone 53-6.7; eBioscience), or CD19 (clone 6D5; eBioscience) for 45 min on ice. For detection of cleaved caspase-3 in lymphocytes, freshly isolated leukocytes from mouse spleens were stained with phycoerythrin-conjugated control antibodies or antibodies against mouse leukocyte antigens, CD4, CD8a, or CD19 for 45 min on ice. Subsequently, cells were fixed with 2% formaldehyde, washed with PBS containing 0.5% bovine serum albumin, and stained with antibody against mouse cleaved caspase-3 (clone Asp175; Cell signaling) before cells were incubated with the fluorescein isothiocyanate-conjugated secondary antibody. The stained cells were analyzed by a FACSCalibur (BD Biosciences) using WinMDI software.
Western blotting
Mouse thymuses were homogenized, washed with PBS, and treated with cell lysis buffer (Cell signaling). Mouse spleens were homogenized, treated twice with buffer to lyse red blood cells, washed with RPMI medium containing 10% fetal bovine serum and then with PBS, and treated with cell lysis buffer. Cell lysates were separated by 12% SDS and transferred to membranes. Membranes were probed with antibodies against mouse cleaved caspase-3 (clone Asp175), Bcl-xL (Cell signaling), or β-actin (clone C4; Millipore) followed by donkey anti-rabbit or anti-mouse secondary antibodies conjugated with horseradish peroxidase (Jackson ImmunoResearch Laboratories, Inc). The protein bands were developed using an enhanced chemiluminescence kit (Millipore).
Cytokine and chemokine measurement
Mouse blood was processed into serum. Brains harvested from mice perfused with PBS were frozen at À80 1C for more than 2 h, thawed, and homogenized in PBS containing protease inhibitor cocktail (Sigma-Aldrich). The brain homogenates were centrifuged to obtain supernatants. The sera and brain supernatants were subjected to enzyme-linked immunosorbent assays (ELISAs) to measure mouse CCL5, CXCL10, IL-6 (R&D Systems), and IFN-β (PBL InterferonSource) using commercially available kits according to the manufacturer's instructions.
Statistical analyses
Data are expressed as means 7standard errors (SE). For statistical comparison, Kaplan-Meier survival curves were analyzed by a log-rank test, disease scores were analyzed by a Wilcoxon signed-rank test, and tissue viral titers were analyzed by a Mann-Whitney U test. The rest of data were analyzed by a Student t test. All p values are for two-tailed significance tests. A p value of o0.05 is considered statistically significant.
